“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report
Duccio Papanti, Fabrizio Schifano, Giulia Botteon, F. Bertossi, Jason Mannix, Daniela Vidoni, Matteo Impagnatiello, Elisabetta Pascolo‐Fabrici, Tommaso Bonavigo
Human Psychopharmacology: Clinical and Experimental July 1, 2013 DOI: 10.1002/hup.2312 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review with case report Peer reviewed |
|---|---|
| Population | SC users, primarily teenagers and young adults |
| Keywords | Psychosis Exacerbation Psychopathology Synthetic cannabinoids Clinical psychology |
| Citations | 191 |
| Key findings | Synthetic cannabimimetics may trigger acute psychosis in vulnerable individuals and exacerbate psychotic episodes in those with a previous psychiatric history. |
Abstract
Objectives: The use of synthetic cannabimimetics (SC; "spice" drugs) is increasing, especially among teenagers and young adults. In parallel with this, the number of studies describing intoxication episodes associated with psychotic symptoms in SC users is growing. We present both a systematic review of the related literature and a case report, which seems to highlight the existence of a possible association between SC use and psychosis.
Methods: Some 223 relevant studies were here identified and reviewed. Out of these, 120 full text articles were assessed for eligibility, and 41 were finally included in the systematic review.
Results: According to the available data from the studies here identified, SC's average age of users was 22.97 years, and the male/female ratio was 3.16:1. SC compounds most often reported in studies using biological specimen analysis were JWH-018, JWH-073, JWH-122, CP-47,497, and JWH-250. Mounting evidence seemed to suggest that psychotic symptoms such as hallucinations and delusions may occur in acute/chronic SC users.
Conclusions: Although a clear causal link may not be here identified, the available evidence suggests that SC can trigger the onset of acute psychosis in vulnerable individuals and/or the exacerbation of psychotic episodes in those with a previous psychiatric history.
Citations in the library
Cited by 46
- Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis World Psychiatry September 22, 2016
- Novel psychoactive substances of interest for psychiatry World Psychiatry February 1, 2016
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Legal highs: staying on top of the flood of novel psychoactive substances Therapeutic Advances in Psychopharmacology January 26, 2015
and 41 more in the library
Cites 15
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Brazilian Journal of Medical and Biological Research April 1, 2006
- Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases The British Journal of Psychiatry November 30, 2005
- Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light Frontiers in Behavioral Neuroscience 2011
and 10 more in the library